EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer

Chang Zhang, Shi-Hao Wu, Lei Jin, Liang Lu, Ji Li, Shui Jin

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.124022 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Immune checkpoint inhibitors (ICIs) show limited efficacy as monotherapy in microsatellite stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC), largely due to an immunosuppressive tumor microenvironment with low T-cell infiltration. Preclinical studies suggest chemotherapy induces immunogenic cell death, while anti-angiogenic agents normalize tumor vasculature, potentially synergizing with ICIs to enhance antitumor immunity. However, real-world evidence for this combination remains insufficient, and whether clinical factors like tumor location or metastasis pattern influence outcomes requires validation. This study evaluated ICI-based combination therapy in MSS/pMMR mCRC using propensity score-based methods. AIM To evaluate ICI-based combination therapy efficacy and explore prognostic modeling and dynamic inflammatory biomarkers in MSS/pMMR mCRC. METHODS A total of 123 patients with MSS/pMMR mCRC were retrospectively enrolled. ICI-based combination therapy was compared with chemotherapy plus bevacizumab alone. Propensity score matching and inverse probability of treatment weighting were applied to reduce confounding, and E-value analysis assessed unmeasured confounding. The primary endpoint was progression-free survival (PFS). A prognostic nomogram was developed and temporally validated. Associations between post-treatment changes in inflammatory biomarkers and PFS were also evaluated. RESULTS After propensity score matching, ICI-based therapy was associated with longer PFS (hazard ratio = 0.486, P = 0.026), with consistent inverse probability of treatment weighting findings. Multivariable regression identified combination therapy as independently favorable and liver metastasis as unfavorable for PFS. Subgroup analyses suggested numerically greater benefits in right-sided and non-liver-metastasis patients, but interaction tests were not significant. A prognostic nomogram showed moderate discrimination temporally (C-index: 0.676-0.695). In exploratory analyses, elevated post-treatment neutrophil-to-lymphocyte ratio and systemic immune-inflammation index were associated with worse PFS in the overall cohort. Grade ≥ 3 adverse event rates were comparable between groups. CONCLUSION ICI-based combination therapy improved PFS with manageable safety in MSS/pMMR mCRC. Nomogram and dynamic neutrophil-to-lymphocyte ratio/systemic immune-inflammation index monitoring may facilitate risk stratification and warrant prospective validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →